SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep. 17, 2012-- Exelixis, Inc. (NASDAQ: EXEL) today announced that its lead compound, cabozantinib, will be the subject of three clinical data presentations at the European Society for Medical Oncology (ESMO) 2012 Congress. During the meeting, which will be held from September 28 to October 2, 2012, in Vienna, Austria, investigators will present data from ongoing trials of cabozantinib in medullary thyroid cancer, castration-resistant prostate cancer, and non-small cell lung cancer.

The full roster of cabozantinib data presentations expected at the meeting is as follows (all times Central European):

Oral Presentation

• “Cabozantinib (XL184) at 40 mg in patients with metastatic castration resistant prostate cancer (mCRPC): Results of a phase 2 non-randomized expansion cohort (NRE)” (Abstract #897O)
  
  Dr. Johann de Bono, Royal Marsden Hospital & Institute of Cancer Research, Sutton, UK
  Oral abstract session: Genitourinary tumors, prostate I
  Sunday, September 30, 2012
  11:45 a.m. CEST
  Hall D

Poster Discussions

• “Molecular profile and anti-tumor activity in non-small cell lung cancer (NSCLC) patients (pts) in a phase 1 study of cabozantinib (XL184) in Japan” (Abstract #1708PD)
  
  Dr. Hiroshi Nokihara, National Cancer Center Hospital, Tokyo, Japan
  Poster discussion session: Developmental therapeutics
  Sunday, September 30, 2012
  Poster on display starting at 9:30 a.m. CEST; respective discussion session starting at 1:00 p.m.
  Hall H

• “Clinical activity and pharmacokinetics (PK) of cabozantinib (XL184) in patients with progressive medullary thyroid carcinoma (MTC)” (Abstract #445PD)
  
  Dr. Ezra Cohen, University of Chicago, Chicago, IL
  Poster discussion session: Developmental therapeutics
  Sunday, September 30, 2012
  Poster on display starting at 9:30 a.m. CEST; respective discussion session starting at 1:00 p.m.
  Hall H

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib (formerly known as XL184), its most advanced product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, broadly-active, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at www.exelixis.com.

Source: Exelixis, Inc.

Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President,
Investor Relations and
Corporate Communications
cbutler@exelixis.com